North China Pharmaceutical Co Ltd (600812) — Cash Flow Reinvestment Rate
North China Pharmaceutical Co Ltd (600812) has a Cash Flow Reinvestment Rate of 0.85x as of September 2025, reinvesting CN¥144.38 Million (capex CN¥144.38 Million ) from operating cash flow of CN¥170.24 Million. See North China Pharmaceutical Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
North China Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2000–2025)
Historical reinvestment intensity for North China Pharmaceutical Co Ltd across 22 annual periods. For the full cash flow conversion analysis, see North China Pharmaceutical Co Ltd (600812) cash flow conversion.
Annual Cash Flow Reinvestment Rate for North China Pharmaceutical Co Ltd (2000–2025)
Year-by-year capital reinvestment analysis for North China Pharmaceutical Co Ltd. See North China Pharmaceutical Co Ltd (600812) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.66x | CN¥781.54 Million | CN¥1.18 Billion | CN¥542.01 Million | ▼ -44.0% |
| 2024 | 1.19x | CN¥1.46 Billion | CN¥1.23 Billion | CN¥784.22 Million | ▼ -19.3% |
| 2023 | 1.47x | CN¥1.50 Billion | CN¥1.02 Billion | CN¥623.04 Million | ▲ +167.5% |
| 2022 | 0.55x | CN¥551.58 Million | CN¥1.00 Billion | CN¥549.58 Million | ▼ -26.8% |
| 2021 | 0.75x | CN¥787.50 Million | CN¥1.05 Billion | CN¥547.50 Million | ▼ -44.1% |
| 2020 | 1.34x | CN¥1.01 Billion | CN¥752.15 Million | CN¥1.01 Billion | ▲ +51.7% |
| 2019 | 0.88x | CN¥648.46 Million | CN¥732.97 Million | CN¥645.97 Million | ▲ +34.6% |
| 2018 | 0.66x | CN¥509.13 Million | CN¥774.33 Million | CN¥506.64 Million | ▼ -68.5% |
| 2017 | 2.09x | CN¥599.69 Million | CN¥287.25 Million | CN¥399.69 Million | ▼ -55.0% |
| 2015 | 4.64x | CN¥567.81 Million | CN¥122.50 Million | CN¥367.81 Million | ▲ +62.5% |
| 2014 | 2.85x | CN¥258.30 Million | CN¥90.56 Million | CN¥258.30 Million | ▼ -42.9% |
| 2011 | 4.99x | CN¥1.14 Billion | CN¥227.60 Million | CN¥1.14 Billion | ▲ +1279.5% |
| 2009 | 0.36x | CN¥366.10 Million | CN¥1.01 Billion | CN¥366.10 Million | ▲ +184.8% |
| 2008 | 0.13x | CN¥138.00 Million | CN¥1.09 Billion | CN¥138.00 Million | ▼ -14.1% |
| 2007 | 0.15x | CN¥98.27 Million | CN¥664.37 Million | CN¥98.27 Million | ▲ +70.8% |
| 2006 | 0.09x | CN¥51.72 Million | CN¥597.12 Million | CN¥51.72 Million | ▼ -89.5% |
| 2005 | 0.82x | CN¥184.67 Million | CN¥224.17 Million | CN¥184.67 Million | ▼ -26.6% |
| 2004 | 1.12x | CN¥348.50 Million | CN¥310.39 Million | CN¥348.50 Million | ▲ +47.2% |
| 2003 | 0.76x | CN¥442.77 Million | CN¥580.32 Million | CN¥442.77 Million | ▲ +150.8% |
| 2002 | 0.30x | CN¥224.68 Million | CN¥738.50 Million | CN¥224.68 Million | ▼ -41.7% |
| 2001 | 0.52x | CN¥191.79 Million | CN¥367.28 Million | CN¥191.79 Million | ▼ -28.5% |
| 2000 | 0.73x | CN¥97.52 Million | CN¥133.49 Million | CN¥97.52 Million | — |